Neurotech International Ltd. (AU:NTI) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurotech International Ltd has announced an upcoming presentation at the 9th World Rett Syndrome Congress, where Professor Carolyn Ellaway will discuss their clinical trial for Rett Syndrome treatment using cannabis-derived NTI164. The company is also awaiting the FDA’s decision on their Orphan Drug Designation request for NTI164. Neurotech is known for its focus on paediatric neurological disorders and has shown promising results in past trials for various conditions, including Autism Spectrum Disorder and PANDAS/PANS.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.